David A. Siegel Harvard Bioscience Inc Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Harvard Bioscience Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 39,956 shares of HBIO stock, worth $83,907. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,956
Previous 75,656
47.19%
Holding current value
$83,907
Previous $215,000
50.23%
% of portfolio
0.0%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding HBIO
# of Institutions
96Shares Held
31.5MCall Options Held
700Put Options Held
2.1K-
Black Rock Inc. New York, NY2.84MShares$5.97 Million0.0% of portfolio
-
Punch & Associates Investment Management, Inc. Edina, MN2.77MShares$5.82 Million0.44% of portfolio
-
Harvey Partners, LLC Tarrytown, NY2.72MShares$5.7 Million0.87% of portfolio
-
Amh Equity LTD2.39MShares$5.02 Million8.88% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.15MShares$4.52 Million0.0% of portfolio
About HARVARD BIOSCIENCE INC
- Ticker HBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 41,636,500
- Market Cap $87.4M
- Description
- Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...